Scarica l'app Stockscreener
2.03
5.14%
-0.11
Dopo l'orario di chiusura:
2.00
-0.03
-1.48%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$2.14
Aprire:
$2.1
Volume 24 ore:
46,165
Relative Volume:
0.14
Capitalizzazione di mercato:
$3.83M
Reddito:
-
Utile/perdita netta:
$-8.77M
Rapporto P/E:
-0.0739
EPS:
-27.4806
Flusso di cassa netto:
$-8.14M
1 W Prestazione:
+9.14%
1M Prestazione:
-9.78%
6M Prestazione:
-78.23%
1 anno Prestazione:
-87.56%
Intervallo 1D:
$1.95
$2.10
Intervallo di 1 settimana:
$1.75
$2.20
Portata 52W:
$1.75
$17.84
Enveric Biosciences Inc Stock (ENVB) Company Profile
Nome
Enveric Biosciences Inc
Settore
Industria
Telefono
(617) 444-8400
Indirizzo
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
2.03 | 3.83M | 0 | -8.77M | -8.14M | -27.48 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Enveric Biosciences Inc Borsa (ENVB) Ultime notizie
If You Invested $1,000 in Enveric Biosciences Inc (ENVB) - Stock Titan
Enveric (ENVB) asks shareholders to OK 1-for-5–1-for-50 reverse split; raises authorized shares - Stock Titan
ENVB Technical Analysis & Stock Price Forecast - Intellectia AI
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates - Investing News Network
ENVB Should I Buy - Intellectia AI
Enveric Biosciences Reports Q4 2025 Financial Results - Intellectia AI
Enveric Biosciences Increceives U.S. patent for Evm301 series of drug candidates on March 17 - MarketScreener
Enveric Biosciences (ENVB) Secures U.S. Patent for EVM301 Series Molecules - GuruFocus
ENVB Forecast, Price Target & Analyst Ratings | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 - marketscreener.com
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 - National Today
Short Interest in Enveric Biosciences, Inc. (NASDAQ:ENVB) Drops By 20.6% - Defense World
Enveric Biosciences Reports 2025 Financial Results and Advances EB-003 Non-Hallucinogenic Neuroplastogen Toward Clinical Trials - Minichart
Enveric Biosciences: Advancing Non-Hallucinogenic Psychedelic Drug Development for Mental Health Disorders - Minichart
Enveric Biosciences Inc. (ENVB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Enveric Biosciences recently announced its financial results for the fourth quarter and full year of fiscal 2025, and provided an update on the latest operational developments of the company. - Bitget
Enveric Biosciences 10-K: Pre-revenue, $8.77M operating loss, $8.77M net loss - TradingView
Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Enveric Biosciences (ENVB) warns of going concern risk in 2025 report - stocktitan.net
Enveric Biosciences (NASDAQ: ENVB) advances EB-003 and details 2025 loss - Stock Titan
Enveric Biosciences Stock Prices in Perfection—But Financial Runway Remains a Looming Risk - bitget.com
Enveric Biosciences Reports Financial Results - Moomoo
ENVB Q4'25 Earnings: EPS estimate is (55.80) USD - tradingview.com
Gilgamesh withdraws patent fight against Enveric after $1.2 billion AbbVie deal, CEO says key drug claims now uncontested - MSN
S P Trends: Is Enveric Biosciences Inc a potential multi bagger2026 Volatility Report & Fast Gaining Stock Reports - baoquankhu1.vn
Enveric Biosciences rallies on fresh mechanistic findings for EB-003 - MSN
Enveric Biosciences, Inc. (ENVB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Forecast Cut: Can Enveric Biosciences Inc lead its sector in growth2026 Major Catalysts & Proven Capital Preservation Methods - baoquankhu1.vn
Enveric Biosciences Inc (ENVB) Stock Price, Quote, News & History - Benzinga
Enveric Biosciences (ENVB) Expected to Announce Earnings on Friday - Defense World
Enveric Biosciences Announces Registration of Five Trademarks - Investing News Network
Enveric Biosciences (ENVB) Secures Trademark Registrations in Ca - GuruFocus
Enveric Biosciences announces withdrawal of petition against its patent — ENVB stock rises - MSN
Enveric Biosciences secures Canadian trademark registrations By Investing.com - Investing.com Canada
Enveric Biosciences announces registration of five trademarks - marketscreener.com
Bull Bear: Can Enveric Biosciences Inc sustain its profitabilityStock Surge & Short-Term Trading Alerts - baoquankhu1.vn
Patterns Watch: Is Enveric Biosciences Inc stock forming a cup and handle2025 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Stocktwits
ENVB SEC FilingsEnveric Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VIX Spike: Is APREs ROE strong enoughWeekly Stock Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
ENVB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Weekly Trades: Can SUUN sustain earnings growthMarket Growth Summary & Weekly Return Optimization Plans - baoquankhu1.vn
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy - microdose.buzz
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent - Investing News Network
Enveric Biosciences announces withdrawal of PGR petition filed by Gilgamesh Pharmaceuticals against its patent - marketscreener.com
Biopharmaceutical company Enveric Biosciences announced today that Gilgamesh Pharmaceuticals has officially withdrawn its post-grant review request for a patent previously filed against Enveric Biosciences. - Bitget
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now UncontestedEnveric Biosciences (NASDAQ:ENVB) - Benzinga
Enveric Biosciences Inc Azioni (ENVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):